Workflow
tafoxiparin
icon
Search documents
Karolinska Development’s portfolio company Dilafor receives patent in the US for tafoxiparin in priming of labor
Globenewswire· 2025-10-03 06:30
Core Viewpoint - Karolinska Development's portfolio company Dilafor has received a US patent for its drug candidate tafoxiparin, which is aimed at priming labor, marking a significant step as it progresses into Phase 3 clinical trials [1][2][3]. Group 1: Patent and Development - The US Patent and Trademark Office has granted a patent for tafoxiparin, providing intellectual property protection until at least May 2043 [2]. - Tafoxiparin is designed to prepare the cervix and uterus for labor, potentially increasing the likelihood of normal vaginal deliveries and reducing the need for traditional hospital-based induction treatments [3]. - The drug is positioned to meet new national guidelines recommending labor induction at 39 weeks in the US and 40-41 weeks in Europe, which may lead to an increase in births requiring medical intervention [3]. Group 2: Company Insights - Karolinska Development holds a 3% direct ownership and a 29% indirect ownership interest in Dilafor [5]. - The CEO of Karolinska Development, Viktor Drvota, emphasized the importance of strengthening intellectual property as Dilafor advances in clinical development, highlighting the potential for a safe at-home treatment option for pregnant women [4]. - The company focuses on identifying and investing in breakthrough medical innovations in the Nordic region, aiming to create and grow companies that can deliver impactful medical products [6][8].
Interim Report - January-March 2025
Globenewswire· 2025-04-30 06:00
Core Insights - Karolinska Development AB reported high developmental intensity levels in its portfolio companies during Q1 2025, with many making significant progress [1] Significant Events During Q1 - AnaCardio secured SEK 205 million in a Series A extension financing round and reported positive results from a phase 1b/2a study of AC01 for heart failure [4] - Dilafor completed regulatory meetings with the FDA and European Health Agencies for tafoxiparin, aligning on pivotal Phase 3 study designs [4] - Promimic published positive results on bacterial growth reduction on its HAnano Surface implant [4] - AnaCardio initiated dosing for the phase 2a part of the GOAL-HF1 clinical study, with results expected by year-end [4] - PharmNovo received positive feedback from the FDA regarding its drug candidate PN6047 in a pre-IND meeting [4] - Umecrine Cognition faced delays in its clinical trial for golexanolone due to production issues but reported no safety concerns [4] - Umecrine Cognition presented preclinical data on golexanolone at an international conference [4] - Viktor Drvota took over as CEO of Umecrine Cognition while remaining CEO of Karolinska Development [4] Financial Update for Q1 - The net profit/loss for Q1 was SEK -14.2 million, compared to SEK 0.2 million in Q1 2024 [4] - Earnings per share were SEK -0.05, down from SEK 0.00 in Q1 2024 [4] - Change in fair value of shares in portfolio companies was SEK -3.5 million, influenced by a downturn in Modus Therapeutics' share price [4] - Total fair value of the portfolio was SEK 1,434.2 million, a decrease of SEK 17.3 million from the previous quarter [9] - Net asset value was SEK 1,230.4 million, with a per-share value of SEK 4.6 [9] - Net sales were SEK 0.5 million, unchanged from Q1 2024 [9] - Karolinska Development invested SEK 15.5 million in portfolio companies during Q1 2025, up from SEK 12.0 million in Q1 2024 [9] - Cash and cash equivalents increased by SEK 9.0 million, totaling SEK 51.1 million by March 31, 2025 [9]